GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation ...Middle East

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment...

Hence then, the article about genfleet announces the first approval of a kras g12c inhibitor in china for treatment of advanced non small cell lung cancer patients harboring kras g12c mutation was published today ( Friday 23/08/2024 - 02:37 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation )

Also on site :

• ‘The Young and the Restless’ Star Dee Freeman Dead at 66
• “Esto es una recalibración”: el gabinete de Trump teme que nadie esté a salvo tras los despidos de Bondi y Noem
• New Uncharted game teased? Director post hints at franchise return